Article

Ophthalmic imaging product receives 510(k) clearance

Welch Allyn has received 510(k) clearance from the FDA for the Welch Allyn iExaminerT, which allows providers to manipulate images using the iPhone 4 or 4S.

 

Skaneateles Falls, NY-Welch Allyn has received 510(k) clearance from the FDA for the iExaminerT. The product consists of a hardware adapter and associated software that allows healthcare providers to capture, store, send, and retrieve images from the Welch Allyn PanOpticT Ophthalmoscope using the iPhone 4 or 4S.

“The iExaminer allows healthcare providers to capture and share [easily] the images of a fundus in a moment's notice, helping to improve the quality of care provided-especially for remote users who may not have easy access to specialists,” said Rick Farchione, senior manager, physical assessment at Welch Allyn. “It will increase workflow efficiency by allowing providers to capture and share images from any clinical environment. It is a low-cost way to capture eye imaging [digitally] and will also make it easier for providers to share images with their patients, helping to improve patient knowledge and compliance.”

The iExaminer adapter aligns the optical access of the PanOptic to the visual axis of the iPhone 4 or 4S camera to capture high-resolution pictures of a patient’s fundus and retinal nerve. The iExaminer software application then allows physicians to save images to a patient file, as well as e-mail and print the images.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
CIME 2025: Neda Shamie, MD, on expanding options in pharmacological presbyopia management
© 2025 MJH Life Sciences

All rights reserved.